Publication | Closed Access
ALISPORIVIR - A HOST-TARGETING ANTIVIRAL, PROVIDES LOW VIRAL BREAKTHROUGH RATE AND HIGH BARRIER TO RESISTANCE IN HCV GENOTYPE 1 TREATMENT-NAiVE PATIENTS IN THE PHASE IIB ESSENTIAL STUDY
11
Citations
0
References
2011
Year
Unknown Venue
Viral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirologyHost-targeting AntiviralAntiviral ResponseInfection ControlAntiviral DrugMedicine
No additional data available for this publication yet. Check back later!